Skip to main content
Equibles

SMT · Sahajanand Medical Technologies Limited · Documents

Use SMT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SMT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
533.95 INR +29.30 (+5.81%) At close · Nov 13
Rebalance outlook locked
Market Cap
54.27B INR
Shares
101.65M
Volume · Nov 13 1.93M Avg daily vol (14 sessions) 2.7M

The company's reports, filings, earnings calls and investor events, most recent first. Search these from Claude or ChatGPT →

Earnings call Q2 2027 earnings call Held Nov 5, 2026
2026
Nov 5
Earnings call
Record Results Drive EBITDA Margin Expansion

SMT reported quarter two FY 2027 revenue of around INR373 crores, up 24.7%, and EBITDA of INR65 crores, up 36.6%, lifting margin to 17.6%. Sironity was commercialized in India, while AVDC 1.5 received CE approval.

3 source passages
Quarter two FY 2027 was a record quarter for SMT, with the highest-ever revenue, EBITDA, and PAT. Revenue grew 24.7% to around INR373 crores. EBITDA grew faster, up 36.6% to INR65 crores, and the EBITDA margin rose from 16% to 17.6%. Sironity, our sirolimus drug-coated balloon, is now commercialized in India. On the delivery side, AVDC 1.5 also received the CE approval earlier in the year. Open the document at this passage
Showing 1–1 of 1 documents